PAP
SPRB

Persistent Asset Partners’s Spruce Biosciences SPRB Stock Holding History

Persistent Asset Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415K Buy
7,677
+5,149
+204% +$288K 0.12% 132
2026
Q1 		$165K Buy
+2,528
New +$174K 0.06% 211

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Persistent Asset Partners's SPRB Position: Q2 2026 in Review

Persistent Asset Partners increased its Spruce Biosciences (SPRB) stake by 204% in Q2 2026, buying an estimated $288K and bringing the position to 7,677 shares worth $415K. The position accounts for 0.12% of the portfolio, ranked #132.

Persistent Asset Partners first reported a position in SPRB in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Persistent Asset Partners held 7,677 shares of Spruce Biosciences worth $415K as of Q2 2026.
  • Persistent Asset Partners bought 5,149 Spruce Biosciences shares in Q2 2026, an estimated $288K.
  • Spruce Biosciences made up 0.12% of Persistent Asset Partners's portfolio in Q2 2026, its #132 holding.
  • Persistent Asset Partners first reported a position in Spruce Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.